Literature DB >> 27895132

Protection against Streptococcus pneumoniae Invasive Pathogenesis by a Protein-Based Vaccine Is Achieved by Suppression of Nasopharyngeal Bacterial Density during Influenza A Virus Coinfection.

M Nadeem Khan1, Qingfu Xu2, Michael E Pichichero2.   

Abstract

An increase in Streptococcus pneumoniae nasopharynx (NP) colonization density during a viral coinfection initiates pathogenesis. To mimic natural S. pneumoniae pathogenesis, we commensally colonized the NPs of adult C57BL/6 mice with S. pneumoniae serotype (ST) 6A or 8 and then coinfected them with mouse-adapted H1N1 influenza A virus (PR/8/34). S. pneumoniae established effective commensal colonization, and influenza virus coinfection caused S. pneumoniae NP density to increase, resulting in bacteremia and mortality. We then studied histidine triad protein D (PhtD), an S. pneumoniae adhesin vaccine candidate, for its ability to prevent invasive S. pneumoniae disease in adult and infant mice. In adult mice, the efficacy of PhtD vaccination was compared with that of PCV13. Vaccination with PCV13 led to a greater reduction of S. pneumoniae NP density (>2.5 log units) than PhtD vaccination (∼1-log-unit reduction). However, no significant difference was observed with regard to the prevention of S. pneumoniae bacteremia, and there was no difference in mortality. Depletion of CD4+ T cells in PhtD-vaccinated adult mice, but not PCV13-vaccinated mice, caused a loss of vaccine-induced protection. In infant mice, passive transfer of antisera or CD4+ T cells from PhtD-vaccinated adult mice led to a nonsignificant reduction in NP colonization density, whereas passive transfer of antisera and CD4+ T cells was needed to cause a significant reduction in NP colonization density. For the first time, these data show an outcome with regard to prevention of invasive S. pneumoniae pathogenesis with a protein vaccine similar to that which occurs with a glycoconjugate vaccine despite a less robust reduction in NP bacterial density.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  pneumococcal

Mesh:

Substances:

Year:  2017        PMID: 27895132      PMCID: PMC5278163          DOI: 10.1128/IAI.00530-16

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  50 in total

1.  Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.

Authors:  D E Briles; E Ades; J C Paton; J S Sampson; G M Carlone; R C Huebner; A Virolainen; E Swiatlo; S K Hollingshead
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens.

Authors:  Fabrice Godfroid; Philippe Hermand; Vincent Verlant; Philippe Denoël; Jan T Poolman
Journal:  Infect Immun       Date:  2010-10-18       Impact factor: 3.441

Review 3.  Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly.

Authors:  Tobias R Kollmann; Ofer Levy; Ruth R Montgomery; Stanislas Goriely
Journal:  Immunity       Date:  2012-11-16       Impact factor: 31.745

4.  Density and duration of pneumococcal carriage is maintained by transforming growth factor β1 and T regulatory cells.

Authors:  Daniel R Neill; William R Coward; Jenna F Gritzfeld; Luke Richards; Francesc J Garcia-Garcia; Javier Dotor; Stephen B Gordon; Aras Kadioglu
Journal:  Am J Respir Crit Care Med       Date:  2014-05-15       Impact factor: 21.405

5.  CD4 T cell memory and antibody responses directed against the pneumococcal histidine triad proteins PhtD and PhtE following nasopharyngeal colonization and immunization and their role in protection against pneumococcal colonization in mice.

Authors:  M N Khan; M E Pichichero
Journal:  Infect Immun       Date:  2013-07-29       Impact factor: 3.441

6.  Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children.

Authors:  Michael E Pichichero; Janet R Casey
Journal:  JAMA       Date:  2007-10-17       Impact factor: 56.272

7.  Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine.

Authors:  Monica Bologa; Thierry Kamtchoua; Robert Hopfer; Xiaohua Sheng; Bryony Hicks; Garvin Bixler; Victor Hou; Vildana Pehlic; Tao Yuan; Sanjay Gurunathan
Journal:  Vaccine       Date:  2012-11-02       Impact factor: 3.641

8.  Characterization of inflammatory responses during intranasal colonization with Streptococcus pneumoniae.

Authors:  Alicja Puchta; Chris P Verschoor; Tanja Thurn; Dawn M E Bowdish
Journal:  J Vis Exp       Date:  2014-01-17       Impact factor: 1.355

9.  Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae.

Authors:  Amber M Smith; Frederick R Adler; Ruy M Ribeiro; Ryan N Gutenkunst; Julie L McAuley; Jonathan A McCullers; Alan S Perelson
Journal:  PLoS Pathog       Date:  2013-03-21       Impact factor: 6.823

Review 10.  Unbalanced Neonatal CD4(+) T-Cell Immunity.

Authors:  Isabelle Debock; Véronique Flamand
Journal:  Front Immunol       Date:  2014-08-27       Impact factor: 7.561

View more
  13 in total

1.  Correlation of higher antibody levels to pneumococcal proteins with protection from pneumococcal acute otitis media but not protection from nasopharyngeal colonization in young children.

Authors:  Q Xu; J R Casey; A Almudevar; M E Pichichero
Journal:  Clin Microbiol Infect       Date:  2017-01-28       Impact factor: 8.067

Review 2.  Pneumococcal whole-cell and protein-based vaccines: changing the paradigm.

Authors:  Michael E Pichichero
Journal:  Expert Rev Vaccines       Date:  2017-12       Impact factor: 5.217

3.  Double-Edged Role of Interleukin 17A in Streptococcus pneumoniae Pathogenesis During Influenza Virus Coinfection.

Authors:  Ganesh Ambigapathy; Taylor Schmit; Ram Kumar Mathur; Suba Nookala; Saad Bahri; Liise-Anne Pirofski; M Nadeem Khan
Journal:  J Infect Dis       Date:  2019-07-31       Impact factor: 5.226

4.  Interferon-γ promotes monocyte-mediated lung injury during influenza infection.

Authors:  Taylor Schmit; Kai Guo; Jitendra Kumar Tripathi; Zhihan Wang; Brett McGregor; Mitch Klomp; Ganesh Ambigapathy; Ramkumar Mathur; Junguk Hur; Michael Pichichero; Jay Kolls; M Nadeem Khan
Journal:  Cell Rep       Date:  2022-03-01       Impact factor: 9.995

5.  Lipidation of Haemophilus influenzae Antigens P6 and OMP26 Improves Immunogenicity and Protection against Nasopharyngeal Colonization and Ear Infection.

Authors:  Ravinder Kaur; Michael Pichichero
Journal:  Infect Immun       Date:  2022-04-18       Impact factor: 3.609

6.  Modeling specific antibody responses to natural immunization to predict a correlate of protection against infection before commencing a clinical vaccine trial.

Authors:  Anthony Almudevar; Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

7.  Room Temperature Stable PspA-Based Nanovaccine Induces Protective Immunity.

Authors:  Danielle A Wagner-Muñiz; Shannon L Haughney; Sean M Kelly; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

Review 8.  Streptococcus pneumoniae's Virulence and Host Immunity: Aging, Diagnostics, and Prevention.

Authors:  Lavida R K Brooks; George I Mias
Journal:  Front Immunol       Date:  2018-06-22       Impact factor: 7.561

9.  IL-6 Deficiency Exacerbates Allergic Asthma and Abrogates the Protective Effect of Allergic Inflammation against Streptococcus pneumoniae Pathogenesis.

Authors:  Taylor Schmit; Sumit Ghosh; Ram Kumar Mathur; Tyler Barnhardt; Ganesh Ambigapathy; Min Wu; Colin Combs; M Nadeem Khan
Journal:  J Immunol       Date:  2020-06-15       Impact factor: 5.426

Review 10.  Role of Inflammatory Risk Factors in the Pathogenesis of Streptococcus pneumoniae.

Authors:  Ifrah Sohail; Sumit Ghosh; Santhosh Mukundan; Susan Zelewski; M Nadeem Khan
Journal:  Front Immunol       Date:  2018-10-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.